In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Aveo Pharmaceuticals AVEO, but lowered its price target from $11.00 to $9.00.
Jefferies noted, “Aveo announced a strategic restructuring, which will extend its current cash to year-end 2013. This is an incremental positive, although it does not eliminate the company's near-term search for additional capital. The primary focus for investors remains the regulatory prospects for tivozanib in renal cell carcinoma.”
Aveo Pharmaceuticals closed on Tuesday at $7.87.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in